Comparative Pharmacology
Head-to-head clinical analysis: BELBUCA versus OPANA ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BELBUCA versus OPANA ER.
BELBUCA vs OPANA ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Partial mu-opioid receptor agonist; produces analgesia by binding to mu-opioid receptors in the CNS, with ceiling effect on respiratory depression.
Opana ER (oxymorphone hydrochloride) is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can interact with other opioid receptors at higher doses. The principal therapeutic action is analgesia via activation of mu-opioid receptors in the central nervous system, leading to altered perception and response to pain.
Apply one buccal film to inner cheek every 12 hours. Initiate at 75 mcg once daily or every 12 hours for opioid-experienced patients; titrate in increments of 75-150 mcg every 4 days. Maximum dose: 900 mcg every 12 hours.
Initial: 5 mg orally every 12 hours; titrate by 5-10 mg every 12 hours every 3-7 days; maximum 40 mg every 12 hours.
None Documented
None Documented
Terminal elimination half-life of buprenorphine is approximately 24-42 hours, allowing for twice-weekly dosing of BELBUCA.
Terminal elimination half-life: 11.1–13.8 hours; clinically relevant as steady-state achieved in 2–3 days
Primarily renal (70-80% as metabolites, ~15% as unchanged buprenorphine); biliary/fecal excretion accounts for ~10-20%.
Renal (primarily as glucuronide conjugates and unchanged drug): 85-90%; Fecal: <10%
Category C
Category C
Opioid Analgesic
Opioid Analgesic